enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California. Show more
Location: 70 Doppler, Irvine, CA, 92618, United States | Website: https://www.envveno.com | Industry: Medical Devices | Sector: Healthcare
Market Cap
86.61M
52 Wk Range
$2.03 - $5.70
Previous Close
$4.58
Open
$4.56
Volume
282,988
Day Range
$4.33 - $4.68
Enterprise Value
52.35M
Cash
35.14M
Avg Qtr Burn
-4.279M
Insider Ownership
0.84%
Institutional Own.
20.57%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|